Welcome to HitGen

Investors

688222
RMB
  • Highest
  • Lowest
  • Volume
  • Amount
Up to   Beijing time. There is 15-minute delay in the quoted price.

[ HitGen H1 2023 Report has Released ]

Stock Information

Basic Information

HitGen is a biotech company focused on lead generation and optimization of innovative drug discovery research processes. HitGen has its headquarters based in Chengdu, China. Its core technology is centered around the synthesis and screening of a rapidly expanding and proprietary DNA-encoded compound libraries of novel small and macrocyclic molecules for lead generation.HitGen H1 2023 Report has Released,More details please find(https://www.hitgen.com/en/news-details-311.html).
HitGen Inc.
Stock Code 688222 Registered Capital 400,680,000.00
Registered Address Registered Address Building 1 Floor 3, No.88 South Keyuan Road, Hi-Tech Zone, Chengdu, Sichuan
Main Business DNA encoded libraries screening, customized design and synthesis of DNA encoded library, specialized chemistry & bioscience services, and innovative drug discovery project licensing.

Announcements

The Board Office is in charge of the information disclosure and investor relations. The secretary of the board is Shiwei Geng.

Tel:

+86 28 85197385

E-mail:

investors@hitgen.com

info@hitgen.com

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information